Birgitta Sparre

Active Biotech (Sweden) — Sweden

Medicine · Health Sciences

6h-index431citations10works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis(3), Systemic Sclerosis and Related Diseases(3), Pharmacogenetics and Drug Metabolism(2), Urticaria and Related Conditions(2), IL-33, ST2, and ILC Pathways(2)

Publications10 total

An open-label study to evaluate biomarkers and safety in systemic sclerosis patients treated with paquinimod
Arthritis Research & Therapy·2021· 36 citedOpen Access
Paquinimod reduces skin fibrosis in tight skin 1 mice, an experimental model of systemic sclerosis
Journal of Dermatological Science·2016· 49 citedOpen Access
A clinical and microbiological study on the enantiomers of delmopinol
Acta Odontologica Scandinavica·2016· 6 citedOpen Access
FRI0496 An Open-Label Study to Evaluate Biomarkers and Safety in Systemic Sclerosis (SSC) Patients Treated with Paquinimod (ABR-215757)
Annals of the Rheumatic Diseases·2014· 3 cited
FRI0516 Paquinimod (ABR-215757), an Immunomodulatory Compound, Reduces Fibrosis in the Tight Skin-1 (TSK-1) Model for Systemic Sclerosis
Annals of the Rheumatic Diseases·2014· 1 cited
Pharmacokinetics, tolerability, and preliminary efficacy of paquinimod (ABR‐215757), a new quinoline‐3‐carboxamide derivative: Studies in lupus‐prone mice and a multicenter, randomized, double‐blind, placebo‐controlled, repeat‐dose, dose‐ranging study in patients with systemic lupus erythematosus
Arthritis & Rheumatism·2011· 121 cited
Pharmacokinetics and clinical efficacy of delmopinol in an open rinse time study in healthy volunteers.
PubMed·2011· 7 cited
CYTOCHROME P450 3A4 IS THE MAJOR ENZYME RESPONSIBLE FOR THE METABOLISM OF LAQUINIMOD, A NOVEL IMMUNOMODULATOR
Drug Metabolism and Disposition·2005· 37 cited
<i>In vitro</i>metabolism and<i>in vivo</i>pharmacokinetics of quinoline 3-carboxamide derivatives in various species
Xenobiotica·2005· 6 cited
The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis
Journal of Neuroimmunology·2002· 165 cited

Frequent Co-authors

Helén Tuvesson(7), Helén Nyhlén(4), Marie Törngren(4), Helena Eriksson(4), Mikael Åström(3), Martin Stenström(3), Oliver Distler(3), Tomas Leanderson(2), Ingrid Hallin(2), Janeric Seidegård(2), Roger Hesselstrand(2), Jörg H. W. Distler(2), Gabriela Riemekasten(2), Fredrik Andersson(2), Torgny Sjödin(2), Charlott Brunmark(1), Anna Runström(1), Lennart Ohlsson(1), Thomas Brodin(1), Gunnar Hedlund(1)